Antiretroviral pharmacokinetic changes in special situations: a narrative review




Antiretrovirals; Pharmacokinetic; HIV.


The number of new cases of HIV infection has been steadily increasing. In the world scenario, there is an increase in access to antiretroviral therapy and, currently, 26 million people use antiretrovirals. In Brazil, a country that provides full and free access to antiretrovirals, about 630 thousand people are undergoing treatment. This study aims to describe the pharmacokinetic changes of antiretrovirals in patients with different physiological conditions. A bibliographic survey was carried out with studies related to the use of antiretrovirals in specific groups: extremes of age (newborns and elderly), pregnancy, liver diseases, chronic kidney disease, cardiovascular disease, obesity and metabolic disorders, dietary interactions, use and abuse of legal and illegal drugs and genetic polymorphism. In certain situations, changes in pharmacokinetic parameters such as absorption, distribution, metabolism and excretion were observed, as well as variations in plasma levels of antiretrovirals. In the investigated groups, the importance of dose adjustment is highlighted to increase the effectiveness of antiretrovirals, aiming to provide a more adequate treatment to people living with HIV. 

Author Biography

Cristina Sanches, Universidade Federal de São João del-Rei

Universidade Federal de São João del-Rei (UFSJ), Campus Centro-Oeste Dona Lindu. Rua Sebastião Gonçalves Coelho, 400. Bairro Chanadour. CEP: 35501-296. Divinópolis, Minas Gerais, Brasil. Telefone: (37) 991100301


AIDSINFO. (2018). Recommendations for the use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States. Retrieved from

AIDSINFO. (2019). Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Retrieved from

Araújo, P. D., & Ehrhardt, A. (2015). Avaliação do dano hepático em pacientes HIV positivo sob terapia antirretroviral no município de Carazinho/RS. Saúde e Desenvolvimento Humano, 3(2), 45–54.

Bastos, F. I. P. M., Vasconcellos, M. T. L. de, De Boni, R. B., Reis, N. B. dos, & Coutinho, C. F. de S. (2017). III Levantamento Nacional sobre o uso de drogas pela população brasileira. Rio de Janeiro: ICICT/FIOCRUZ. Retrieved from ICICT/FIOCRUZ website:

Benaboud, S., Hirt, D., Launay, O., Pannier, E., Firtion, G., Rey, E., … Tréluyera, J. M. (2012). Pregnancy-related effects on tenofovir pharmacokinetics: A population study with 186 women. Antimicrobial Agents and Chemotherapy, 56(2), 857–862.

Benaboud, S., Tréluyer, J. M., Urien, S., Blanche, S., Bouazza, N., Chappuy, H., … Hirt, D. (2012). Pregnancy-related effects on lamivudine pharmacokinetics in a population study with 228 women. Antimicrobial Agents and Chemotherapy, 56(2), 776–782.

Benedetti, M. S., Whomsley, R., & Canning, M. (2007). Drug metabolism in the paediatric population and in the elderly. Drug Discovery Today, 12(15–16), 599–610.

Best, B. M., Mirochnick, M., Capparelli, E. V., Stek, A., Burchett, S. K., Holland, D. T., … Connor, J. D. (2006). Impact of pregnancy on abacavir pharmacokinetics. Aids, Vol. 20, pp. 553–560.

Bracchi, M., Stuart, D., Castles, R., Khoo, S., Back, D., & Boffito, M. (2015). Increasing use of “party drugs” in people living with HIV on antiretrovirals: A concern for patient safety. AIDS, 29(13), 1585–1592.

Brasil. Lei n° 9313, de 13 de novembro de 1996. Dispões sobre a distribuição gratuita de medicamentos aos portadores do HIV e doentes de AIDS. , (1996). Brasília - DF: Diario Oficial da União.

Brasil. (2010). Adesão ao Tratamento Antirretroviral no Brasil: Coletânea de Estudos do Projeto Atar. Retrieved June 2, 2021, from Ministério da Saúde, Secretaria de Vigilância em Saúde Departamento de DST, Aids e Hepatites Virais. website:

Brasil. (2018). Protocolo Clínico e Diretrizes Terapêuticas para Manejo da Infecção pelo HIV em Adultos. Retrieved May 26, 2021, from Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância, Prevenção e Controle das Infecções Sexualmente Transmissíveis, do HIV/Aids e das Hepatites Virais website:

BRASIL. (2019). Boletim epidemiológico. Brasília. Retrieved from

Brito, D. M. S. de. (2012). Guia de cuidados aos pacientes em uso de terapia antirretroviral.

Calcagno, A., Cusato, J., D’Avolio, A., & Bonora, S. (2017). Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs. Clinical Pharmacokinetics, 56(4), 355–369.

Canals, F., Masiá, M., & Gutiérrez, F. (2018). Developments in early diagnosis and therapy of HIV infection in newborns. Expert Opinion on Pharmacotherapy, 19(1), 13–25.

Capparelli, E. V., Mirochnick, M., Dankner, W. M., Blanchard, S., Mofenson, L., McSherry, G. D., … Oram, R. (2003). Pharmacokinetics and tolerance of zidovudine in preterm infants. Journal of Pediatrics, 142(1), 47–52.

CDC. (2017, August). HIV infection and older Americans: The public health perspective. American Journal of Public Health, Vol. 102, pp. 1516–1526.

Chang, P., & Friedenberg, F. (2014). Obesity and GERD. Gastroenterology Clinics of North America, 43(1), 161–173.

Chastain, D. B., Henderson, H., & Stover, K. R. (2015). Epidemiology and Management of Antiretroviral-Associated Cardiovascular Disease. The Open AIDS Journal, 9(1), 23–37.

Connor, E. M., Sperling, R. S., Gelber, R., Kiselev, P., Scott, G., O’sullivan, M. jo, … Balsley, J. (1994). Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. New England Journal of Medicine, 331(18), 1173–1180.

Costantine, M. M. (2014). Physiologic and pharmacokinetic changes in pregnancy. Frontiers in Pharmacology, 5 APR(April), 1–5.

Courlet, P., Stader, F., Guidi, M., Saldanha, S. A., Stoeckle, M., Cavassini, M., … Marzolini, C. (2019). Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging patients enrolled in the Swiss HIV Cohort Study. Aids, 1.

Cressey, T. R., & Lallemant, M. (2007). Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: An update. Infection, Genetics and Evolution, Vol. 7, pp. 333–342. Elsevier.

Dawes Bsc, M., & Chowienczyk Bsc, P. J. (2001). Pharmacokinetics in pregnancy Lecturer in Clinical Pharmacology. 15(6), 819–826.

De Sousa Mendes, M., & Chetty, M. (2019). Are Standard Doses of Renally-Excreted Antiretrovirals in Older Patients Appropriate: A PBPK Study Comparing Exposures in the Elderly Population With Those in Renal Impairment. Drugs in R and D, (0123456789).

Dupin, N., Buffet, M., Marcelin, A. G., Lamotte, C., Gorin, I., Ait-Arkoub, Z., … Peytavin, G. (2002). HIV and antiretroviral drug distribution in plasma and fat tissue of HIV-infected patients with lipodystrophy. AIDS, 16(18), 2419–2424.

Eichelbaum, M., Ingelman-Sundberg, M., & Evans, W. E. (2006). Pharmacogenomics and individualized drug therapy. Annual Review of Medicine, 57, 119–137.

Ekrikpo, U. E., Kengne, A. P., Bello, A. K., Effa, E. E., Noubiap, J. J., Salako, B. L., … Okpechi, I. G. (2018). Chronic kidney disease in the global adult HIV-infected population: A systematic review and meta-analysis. PLoS ONE, 13(4), 1–24.

Ellis, C. L. (2017). HIV associated kidney diseases: Clarifying concordance between renal failure in HIV infection and histopathologic manifestations at kidney biopsy. Seminars in Diagnostic Pathology, 34(4), 377–383.

Estrela, C. (2018). Metodologia Científica: Ciência, Ensino, Pesquisa. Editora Artes Médicas.

Evans, W. E., & Relling, M. V. (1999, October 15). Pharmacogenomics: Translating functional genomics into rational therapeutics. Science, 286(5439), 487–491.

Ferreira, V. M. B. (2004). ÁLCOOL, DROGAS ILÍCITAS E ANTI-RETROVIRAIS. Retrieved from

Friedl, D. B., Aprile, D. C. B., Fino, L. C., Barbosa, D. A., & Belasco, A. G. S. (2009). Evolução da função renal de pacientes portadores do Vírus da Imunodeficiência Humana/ Síndrome da Imunodeficiência Adquirida. Acta Paulista de Enfermagem, 22(spe1), 531–534.

Ganesan, M., Poluektova, L. Y., Kharbanda, K. K., & Osna, N. A. (2018). Liver as a target of human immunodeficiency virus infection. World Journal of Gastroenterology, 24(42), 4728–4737.

Gauthier, I., & Malone, M. (1998). Drug-food interactions in hospitalised patients. Drug Safety, 18(6), 383–393.

Gilbert, E. M., Darin, K. M., Scarsi, K. K., & McLaughlin, M. M. (2015). Antiretroviral pharmacokinetics in pregnant women. Pharmacotherapy, 35(9), 838–855.

Guaraldi, G., Pintassilgo, I., Milic, J., & Mussini, C. (2018). Managing antiretroviral therapy in the elderly HIV patient. Expert Review of Clinical Pharmacology, 11(12), 1171–1181.

Hall, A. M., Hendry, B. M., Nitsch, D., & Connolly, J. O. (2011). Tenofovir-associated kidney toxicity in HIV-infected patients: A review of the evidence. American Journal of Kidney Diseases, 57(5), 773–780.

Hürlimann, D., Chenevard, R., Ruschitzka, F., Flepp, M., Enseleit, F., Béchir, M., … Weber, R. (2006). Effects of statins on endothelial function and lipid profile in HIV infected persons receiving protease inhibitor-containing anti-retroviral combination therapy: A randomised double blind crossover trial. Heart, 92(1), 110–112.

Ishizaki, A., Cuong, N. H., Thuc, P. Van, Trung, N. V., Saijoh, K., Kageyama, S., … Ichimura, H. (2009). Profile of HIV type 1 infection and genotypic resistance mutations to antiretroviral drugs in treatment-naive HIV type 1-infected individuals in Hai Phong, Viet Nam. AIDS Research and Human Retroviruses, 25(2), 175–182.

Jain, R., Chung, S. M., Jain, L., Khurana, M., Lau, S. W. J., Lee, J. E., … Sahajwalla, C. G. (2011). Implications of obesity for drug therapy: Limitations and challenges. Clinical Pharmacology and Therapeutics, 90(1), 77–89.

Jourjy, J., Dahl, K., & Huesgen, E. (2015). Antiretroviral treatment efficacy and safety in older HIV-infected adults. Pharmacotherapy, 35(12), 1140–1151.

Kaspar, M. B., & Sterling, R. K. (2017). Mechanisms of liver disease in patients infected with HIV. BMJ Open Gastroenterology, 4(1), 1–7.

Khalsa, J. H., Talal, A. H., & Morse, G. (2017). Drug–Drug Interactions and Diagnostics for Drug Users With HIV and HIV/HCV Coinfections: Introduction. Clinical Pharmacology in Drug Development, 6(2), 108–117.

Kim, M. H., Ahmed, S., & Abrams, E. J. (2016). Paediatric HIV : Progress on Prevention , Treatment and Cure. 3(3), 219–229.

King, J. R., Kimberlin, D. W., Aldrovandi, G. M., & Acosta, E. P. (2002). Antiretroviral Pharmacokinetics in the Paediatric Population A Review. Infancy, 41(14), 1115–1133.

Klotz, U., Schwab, M., & Treiber, G. (2004). CYP2C19 polymorphism and proton pump inhibitors. Basic and Clinical Pharmacology and Toxicology, 95(1), 2–8.

Ku, C. L., & Smith, B. P. (2011). Dosing in neonates: Special considerations in physiology and trial design. Bone, 23(1), 1–7.

Kumar, S., Rao, P. S. S., Earla, R., & Kumar, A. (2015). Drug-drug interactions between anti-retroviral therapies and drugs of abuse in HIV systems. Expert Opinion on Drug Metabolism and Toxicology, 11(3), 343–355.

Lombardo, M., & Eserian, J. K. (2014). FÁRMACOS E ALIMENTOS: INTERAÇÕES E INFLUÊNCIAS NA TERAPÊUTICA. Infarma - Ciências Farmacêuticas, 26(3), 188–192.

López, J. C., Moreno, S., Jiménez-Oñate, F., Clotet, B., Rubio, R., & Hernández-Quero, J. (2006). A cohort study of the food effect on virological failure and treatment discontinuation in patients on HAART containing didanosine enteric-coated capsules (FOODDle study). HIV Clinical Trials, 7(4), 155–162.

Madelain, V., Le, M. P., Champenois, K., Charpentier, C., Landman, R., Joly, V., … Peytavin, G. (2017). Impact of obesity on antiretroviral pharmacokinetics and immunovirological response in HIV-infected patients: A case-control study. Journal of Antimicrobial Chemotherapy, 72(4), 1137–1146.

Mangoni, A. A., & Jackson, S. H. D. (2004). Age-related changes in pharmacokinetics and pharmacodynamics: Basic principles and practical applications. British Journal of Clinical Pharmacology, 57(1), 6–14.

Mcdowell, J. A., Chittick, G. E., Stevens, C. P., Edwards, K. D., & Stein, D. S. (2000). Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adults. Antimicrobial Agents and Chemotherapy, 44(6), 1686–1690.

Medeiros, J. L., & Ferreira, M. L. H. (1998). Cirrose Hepática e Insuficiência hepática. Terapêutica Clínica. Rio de Janeiro: Guanabara Koogan.

Menezes, A. M., Torelly, J., Real, L., Bay, M., Poeta, J., & Sprinz, E. (2011). Prevalence and risk factors associated to chronic kidney disease in HIV-infected patients on HAART and undetectable viral load in Brazil. PLoS ONE, 6(10).

Metzger, I. F., Souza-Costa, D. C., & Tanus-Santos, J. E. (2006). Farmacogenética: Princípios, aplicações e perspectivas. Medicina, 39(4), 515–521.

Mocroft, A., Kirk, O., Reiss, P., De Wit, S., Sedlacek, D., Beniowski, M., … EuroSIDA Study Group. (2010). Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS, 24(11), 1667–1678.

Nadaleto, B. F., Herbella, F. A. M., & Patti, M. G. (2016). Gastroesophageal reflux disease in the obese: Pathophysiology and treatment. Surgery (United States), 159(2), 475–486.

Naicker, S., Rahmanian, S., & Kopp, J. B. (2015). HIV and chronic kidney disease. Clinical Nephrology, 83, S32–S38.

NCBI. (2019). National Center for Biotechnology Information. Retrieved August 20, 2021, from

Neto, L. F. da S. P., Bassetti, B. R., Fraga, I. H. V., Oliveira Santos, C. R., Ximenes, P. D., & Miranda, A. E. (2016). Nephrotoxicity during tenofovir treatment: A three-year follow-up study in a Brazilian reference clinic. Brazilian Journal of Infectious Diseases, 20(1), 14–18.

Nettles, R. E., Kieffer, T. L., Parsons, T., Johnson, J., Cofrancesco, J., Gallant, J. E., … Flexner, C. (2006). Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clinical Infectious Diseases, 42(8), 1189–1196.

Nuh, O. (2020). Interactions between HIV treatment and recreational drugs. Retrieved May 26, 2021, from Chemsex & recreational drug use website:

Nunes, E. P. (2016). Terapia antirretroviral e função renal. The Brazilian Journal of Infectious Diseases, 2(3), 82–90. Retrieved from

Núñez, M. (2010). Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. Hepatology, 52(3), 1143–1155.

Oliveira, N. M., Ferreira, F. A. Y., Yonamine, R. Y., & Chehter, E. Z. (2014). Drogas antirretrovirais e pancreatite aguda em pacientes com HIV/AIDS: existe alguma associação? Revisão da literatura. Einstein, 12(1). Retrieved from

Pacifici, G. M. (2005). Pharmacokinetics of antivirals in neonate. Early Human Development, 81(9), 773–780.

Pariente, G., Leibson, T., Carls, A., Adams-Webber, T., Ito, S., & Koren, G. (2016). Pregnancy-Associated Changes in Pharmacokinetics: A Systematic Review. PLoS Medicine, 13(11), 1–36.

Pezzani, M. D., Resnati, C., Di Cristo, V., Riva, A., & Gervasoni, C. (2016). Abacavir-induced liver toxicity. Brazilian Journal of Infectious Diseases, 20(5), 502–504.

Post, F. A., & Holt, S. G. (2009). Recent developments in HIV and the kidney. Current Opinion in Infectious Diseases, 22(1), 43–48.

Queiroz, M. A. F., Laurentino, R. V., Amoras, E. da S. G., Araújo, M. S. M. de, Gomes, S. T. M., Lima, S. S., … Machado, L. F. A. (2017). The CYP2B6 G516T polymorphism influences CD4+ T-cell counts in HIV-positive patients receiving antiretroviral therapy in an ethnically diverse region of the Amazon. International Journal of Infectious Diseases, 55, 4–10.

Rakhmanina, N., & Phelps, B. R. (2012). Pharmacotherapy of Pediatric HIV Infection. Pediatric Clinics of North America, 59(5), 1093–1115.

Raposeiras-Roubín, S., & Triant, V. (2016). Ischemic Heart Disease in HIV: An In-depth Look at Cardiovascular Risk. Revista Española de Cardiología (English Edition), 69(12), 1204–1213.

Reynes, J., Pevriere, H., De Boever, C., & Le Moing, V. (2003). Renal tubular injury and severe hypophosphoremia (Fanconi syndrome) associated with tenofovir therapy [poster 717]. In Program an Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections. Boston, USA. Alexandria, VA: Foundation for Retrovirology and Human Health.

Ritschel, W. A., & Kearns, G. L. (2009). Handbook of Basic Pharmacokinetics Including Clinical Applications (7 th ed.). The American Pharmacists Association.

Rodighiero, V. (1989). EFFECTS OF CARDIOVASCULAR DISEASE ON PHARMACOKINETICS SUMMARY. Cardiovascular Drugs and Therapy, 3, 711–730.

Rongkavilit, C., Thaithumyanon, P., Chuenyam, T., Damle, B. D., Limpongsanurak, S., Boonrod, C., … Phanuphak, P. (2001). Pharmacokinetics of stavudine and didanosine coadministered with nelfinavir in human immunodeficiency virus-exposed neonates. Antimicrobial Agents and Chemotherapy, 45(12), 3585–3590.

Santos, W. M. Dos, Secoli, S. R., & Padoin, S. M. de M. (2016). Potential drug interactions in patients given antiretroviral therapy. Revista Latino-Americana de Enfermagem, 24.

Schijvens, A. M., Wildt, S. N. de, & Schreuder, M. F. (2020). Pharmacokinetics in children with chronic kidney disease. Pediatric Nephrology, 35(7), 1153–1172.

Schoen, J. C., Erlandson, K. M., & Anderson, P. L. (2013). Clinical pharmacokinetics of antiretroviral drugs in older persons. Expert Opinion on Drug Metabolism and Toxicology, 9(5), 573–588.

Simões, G. L. D. B. A., Camera, P., Pacheco, A., & Nascimento, R. E. do. (2020). Polimorfismos genéticos no receptor da vitamina D e a suscetibilidade a doenças no Brasil. Revista de Patologia Do Tocantins, 7(2), 83–87.

Singh, H. O., Samani, D., Nain, S., & Dhole, T. N. (2019). Interleukin-10 polymorphisms and susceptibility to ARV associated hepatotoxicity. Microbial Pathogenesis, 133.

Smit, C., Hoogd, S. de, Brüggemann, R. J. M., & Knibbe, C. A. J. (2018). Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters. Expert Opinion on Drug Metabolism and Toxicology, 14(3), 275–285.

Soeria-Atmadja, S., Österberg, E., Gustafsson, L. L., Dahl, M. L., Eriksen, J., Rubin, J., & Navér, L. (2017). Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin. PLoS ONE, 12(9).

Souza, D. S. de, Hora, T. F. da, Padilha, P. de C., Gonçalves, J. C. S., & Peres, W. A. F. (2014). Efeito dos alimentos na biodisponibilidade de medicamentos antirretrovirais: uma revisão sistemática da literatura. Nutrire, 39(2), 243–251.

Souza, J. de, & Storpirtis, S. (2004). Antiretroviral activity and pharmacokinetics properties of lamivudine and zidovudine association. Revista Brasileira de Ciencias Farmaceuticas/Brazilian Journal of Pharmaceutical Sciences, 40(1), 9–19.

Spina, E., Santoro, V., & D’Arrigo, C. (2008). Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: An update. Clinical Therapeutics, 30(7), 1206–1227.

Stader, F., Kinvig, H., Penny, M. A., Battegay, M., Siccardi, M., & Marzolini, C. (2019). Physiologically Based Pharmacokinetic Modelling to Identify Pharmacokinetic Parameters Driving Drug Exposure Changes in the Elderly. Clinical Pharmacokinetics, (0123456789).

Stolbach, A., Paziana, K., Heverling, H., & Pham, P. (2015). A Review of the Toxicity of HIV Medications II: Interactions with Drugs and Complementary and Alternative Medicine Products. Journal of Medical Toxicology, 11(3), 326–341.

Sudano, I., Spieker, L. E., Noll, G., Corti, R., Weber, R., & Lüscher, T. F. (2006). Cardiovascular disease in HIV infection. American Heart Journal, 151(6), 1147–1155.

Sulkowski, M. S., Thomas, D. L., Mehta, S. H., Chaisson, R. E., & Moore, R. D. (2002). Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: Role of hepatitis C and B infections. Hepatology, 35(1), 182–189.

Svärd, J., Spiers, J. P., Mulcahy, F., & Hennessy, M. (2010). Nuclear receptor-mediated induction of CYP450 by antiretrovirals: Functional consequences of NR1I2 (PXR) polymorphisms and differential prevalence in whites and sub-Saharan Africans. Journal of Acquired Immune Deficiency Syndromes, 55(5), 536–549.

Swanepoel, C. R., Atta, M. G., D’Agati, V. D., Estrella, M. M., Fogo, A. B., Naicker, S., … Zeier, M. (2018). Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 93(3), 545–559.

Terada, T., & Hira, D. (2015). Intestinal and hepatic drug transporters: pharmacokinetic, pathophysiological, and pharmacogenetic roles. Journal of Gastroenterology, 50(5), 508–519.

Thapa, R. K., Choi, H. G., Kim, J. O., & Yong, C. S. (2017). Analysis and optimization of drug solubility to improve pharmacokinetics. Journal of Pharmaceutical Investigation, 47(2), 95–110.

Triant, V. A. (2013). Cardiovascular Disease and HIV Infection Virginia. Curr HIV/AIDS, 10(3), 199–206.

UNAIDS. (2019a). Joint United Nations Programme on HIV/AIDS. Retrieved May 28, 2021, from Country fact sheet: Brazil 2019 website:

UNAIDS. (2019b). Joint United Nations Programme on HIV/AIDS. Retrieved May 24, 2021, from

UNAIDS. (2020). Joint United Nations Programme on HIV/AIDS. Retrieved May 24, 2021, from Fact sheet – World Aids Day 2020. Global HIV Statistics website:

Venter, J. C., Adams, M. D., Myers, E. W., Li, P. W., Mural, R. J., Sutton, G. G., … Zhu, X. (2001). The sequence of the human genome. Science, 291(5507), 1304–1351.

Verma, S., & Kaplowitz, N. (2009). Diagnosis, management and prevention of drug-induced liver injury. General Medicine, 58(11), 1555–1564.

Violari, A., PH, D., Steyn, J., Sc, M., Madhi, S. A., Paed, F. C., … Jean-philippe, P. (2008). Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV- infected infants. N Engl J Med. Nov 2008;359(21):2233-2244. 359(21), 2233–2244.

Winston, A., Bloch, M., Carr, A., Amin, J., Mallon, P. W. G., Ray, J., … Emery, S. (2005). Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy. Journal of Antimicrobial Chemotherapy, 56(2), 380–387.

Winter, M. E. (2004). Basic clinical pharmacokinetics (4th ed). United States: Philadelphia : Lippincott Williams & Wilkins, c2004.

Won, C. S., Oberlies, N. H., & Paine, M. F. (2012). Mechanisms underlying food-drug interactions: Inhibition of intestinal metabolism and transport. Pharmacology and Therapeutics, 136(2), 186–201.

Yellepeddi, V. (2016). Princípios da terapia medicamentosa (6 ed.; Artmed, Ed.). Porto Alegre: Whalen, K. et al. Farmacologia Ilustrada.



How to Cite

BERNARDES, G. C. S.; SALES, T. L. S.; SANTOS, M. T. A.; ROCHA, B. G.; COSTA, A. C. de M.; CASTRO, A. P. de; RESENDE, C. A. A.; SANCHES, C. Antiretroviral pharmacokinetic changes in special situations: a narrative review. Research, Society and Development, [S. l.], v. 10, n. 12, p. e108101220198, 2021. DOI: 10.33448/rsd-v10i12.20198. Disponível em: Acesso em: 29 feb. 2024.



Health Sciences